ClinicalTrials.gg
TerminatedNCT00882414Updated Apr 8, 2010

Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)

A Phase 2 interventional study of FERINJECT® (Ferric carboxymaltose) and Placebo in Thrombocytosis and Iron-Deficiency Anemia, sponsored by Vifor Pharma. Terminated at 1 site in Austria. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2010-04-08.

Sponsored by Vifor Pharma (part of CSL Limited) · Phase 2, Interventional, and Treatment

Why this study was terminated
Main objective of study was met. Further recruitment was difficult.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The aim of this study is to show the benefits for patients, with a high platelet count, iron deficiency and IBD, receiving intravenous iron therapy.

Read the detailed description

For the first time a platelet abnormality in IBD was reported in 1968, with a description of an increased platelet count in patients having an exacerbation of clinical activity 1. Since then it has been established that thrombocytosis and platelet activation are common features in IBD2. Both features are strongly connected to thromboembolic events, which are a major cause of patient morbidity and mortality 3. In vitro studies have so far shown that spontaneous platelet aggregation is present in more than 30% of IBD patients compared to none of the controls and besides independent of disease severity 4.

Unfortunately the mechanisms behind the abnormal megakaryopoiesis are not completely understood. Nevertheless platelets can store and produce a large amount of inflammatory mediators and are activated by multiple proinflammatory substances. Therefore, platelets are regarded as a major target in the therapy of inflammatory bowel diseases 5. An increase in systemic cytokine levels such as IL-6 or IL-11 may contribute to enhanced platelet production. Also intestinal bleeding and iron deficiency, which are major symptoms of IBD, may have stimulatory effects on megakaryopoiesis 6.

Previously, we observed a normalization of elevated platelet counts in IBD patients with iron deficiency anemia (IDA) upon treatment with intravenous iron sucrose 7. We therefore believe that iron deficiency is causatively involved in the pathogenesis of thrombocytosis in IBD and intend to investigate the effect of intravenous iron therapy on platelet levels and platelet activation markers in patients with IBD and iron deficiency.

Vifor (International) Inc. has developed a new formulation of parenteral iron, FERINJECT® (5% w/v iron carboxymaltose in a solution of water for injection). Based on preclinical toxicity data and clinical experience, FERINJECT® does not cause anaphylactic reactions or liver toxicity. Based on human pharmacokinetic data, the estimated terminal half-life of FERINJECT® is 16 hours. The analysis of a FERINJECT® positron emission tomography (PET) study in six patients each receiving a single dose of 100mg iron as FERINJECT® demonstrated that, during the initial distribution phase, a major proportion of the dose was distributed to the bone marrow . Red cell utilization of iron was found to be high. After 24 days, patients with IDA showed a red cell utilization of 91% to 99%. Various studies demonstrated that FERINJECT® could be safely administered at doses of up to 1000mg, which is a significant advantage of FERINJECT® over iron sucrose.

A multiple-dose phase I/II study in patients with IBD investigating the safety, efficacy, and kinetics of repeated doses of FERINJECT® has been completed. Patients who were treated at our unit (Medical University of Vienna) were also analyzed regarding the effect of VIT45 on platelet counts. Similar to our experience with iron sucrose, we observed a significant drop in thrombocytosis within 8 weeks pointing again to the direct effect of iron on regulating megakaryopoiesis in vivo8.

This study tries to show the benefits for patients, with a high platelet count, iron deficiency and IBD, receiving intravenous iron therapy.

As with all iron preparations, overdosing with respect to the total amount should be avoided. The maximum infused weekly dose of FERINJECT® will be 500 mg. Based on animal toxicity data and patient experience, FERINJECT® does not cause anaphylactic reactions or liver toxicity at the doses intended for use in this study. However, due to the relatively large doses of iron being administered, patients will be monitored carefully throughout the study for symptoms of iron overload.

Potential benefits to the patients include a decrease of the platelet counts, besides a increase in hemoglobin levels and normalization of iron stores.

Primary Objective:

To evaluate the efficacy of FERINJECT® in reducing elevated platelet counts

Secondary Objectives:

To evaluate the effect of FERINJECT® on coagulation and platelet activation parameters To evaluate the efficacy of FERINJECT® in normalizing iron deficiency To evaluate the change of quality in life and disease activity To evaluate the safety of FERINJECT®

02

Conditions studied

  • Thrombocytosis
  • Iron-Deficiency Anemia

Keywords

  • ferric carboxymaltose
  • platelet
  • thrombocyte
  • ferritin
  • hemoglobin
  • transferrin
03

In context

Thrombocytosis

34 studies on the registry are indexed under Thrombocytosis; 8 are open to participants now.

This study's enrollment of 26 is below the median of 40 across 22 interventional studies indexed under Thrombocytosis.

Browse Thrombocytosis studies →

Lead sponsor

Vifor Pharma is the lead sponsor of 22 studies on the registry; none are open to participants now.

First submitted before Vifor Pharma became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, inpatient or outpatient, aged at least 18 years and not more than 60 years.
  • Have a count >450G/l
  • Transferrin saturation (TfS) \<20% or ferritin \< 100µg/l
  • Previously diagnosed inflammatory bowel disease (Crohn's disease or ulcerative colitis)
  • Females of must have a negative urine pregnancy test at screening and be practicing a highly effective method of during the study and for up to 1 month after the last dose of the study medication. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner. Non-childbearing potential includes being surgically sterilized at least 6 months prior to the study or , defined as amenorrhoea for at least 12 months.
  • Demonstrate the ability to understand the requirements of the study, provide written , abide by the study restrictions, and agree to undergo the required assessments.

Exclusion criteria

Exclusion Criteria:

  • CDAI >220, CAI>6
  • Significant anemia ( \<10.5 g/dl), or anaemia not caused by iron deficiency (e.g. anaemia due to cancer or infection)
  • Blood transfusions or iron therapy during the previous 4 weeks, or erythropoietin treatment within the 8 weeks prior to enrollment.
  • Concomitant therapy with prednisolone above 20mg/d, 6-mercaptopurine, infliximab or azathioprine must have been initiated at least 4 months prior to study and the dose must be stable for at least 8 weeks. Other drugs with known effects on megakaryopoiesis (e.g. interferon-alpha).
  • Severe concomitant disease or need for surgery within 8 weeks
  • Hemochromatosis or other iron-storage disorders (e.g. thalassemia, siderosis, lead poisoning anaemia, porphyria cutanea tarda)
  • Treatment with an drug within the 30 days prior to enrollment
  • Active severe infection or other than carcinoma in situ of the cervix and non-melanoma skin cancer.
  • Bone Marrow Disease (MDS, thalassemia, etc)
  • Active or chronic liver or kidney disease. Serum albumin \<25 g/L or serum creatinine >20 mg/L
  • Significant cardiovascular disease, including myocardial infarction within 12 months prior to study inclusion, congestive heart failure (New York Heart Association) grade III or IV, or poorly controlled hypertension according to the judgment of the investigator. Known to FERINJECT®
  • Positive for 1/HIV 2 antibodies (anti HIV) (HIV: human immunodeficiency virus).
  • Positive for surface-antigen (HBsAg), virus antibody (anti HCV) and evidence for active hepatitis, i.e., abnormal liver function test (LFT) results.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
26 participants (actual)

Study arms

  • Placebo comparator
    ThromboVIT Placebo

    Patients will receive 1 placebo infusion of 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions.

    Drug: Placebo

  • Experimental
    ThromboVIT 1000

    ThromboVIT 1000: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 2 infusions (1000 mg) followed by 1 placebo infusion of 100ml 0.9% sodium chloride.

    Drug: FERINJECT® (Ferric carboxymaltose)

  • Experimental
    ThromboVIT 1500

    Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions (1500 mg).

    Drug: FERINJECT® (Ferric carboxymaltose)

  • Experimental
    ThromboVIT 500

    ThromboVIT 500: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride (500 mg) followed by 2 placebo infusions of 100ml 0.9% sodium chloride every 7 days.

    Drug: FERINJECT® (Ferric carboxymaltose)

Interventions

  • FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.

    Also known as: FERINJECT®

  • DrugPlacebo

    Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.

    Also known as: NaCl 0.9%, saline

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of FERINJECT® in reducing elevated platelet counts

    The primary efficacy endpoint is a decrease of the platelet counts \>25% after 6 weeks.

    Time frame: 6 weeks post baseline

Secondary outcomes

  1. Normalization of platelet levels

    Normalization of platelet levels

    Time frame: 6 weeks post baseline

  2. Change in platelet activation markers (p-selectin, sCD40L), thrombopoietin and reticulated thrombocytes

    Change in platelet activation markers (p-selectin, sCD40L), thrombopoietin and reticulated thrombocytes

    Time frame: 6 weeks post baseline

  3. Change in coagulation parameters (PTT, PT, factors of the intrinsic coagulation pathway)

    Change in coagulation parameters (PTT, PT, factors of the intrinsic coagulation pathway)

    Time frame: 6 weeks post baseline

  4. Change in iron parameters (ferritin, hemoglobin, transferrin, transferrin saturation, soluble transferrin-receptor, hepcidin)

    Change in iron parameters (ferritin, hemoglobin, transferrin, transferrin saturation, soluble transferrin-receptor, hepcidin)

    Time frame: 6 weeks post baseline

  5. Change in quality of life (IBDQ, SF-36, FACT-An or similar) and disease activity

    Change in quality of life (IBDQ, SF-36, FACT-An or similar) and disease activity (CDAI, CAI=Clinical activity scores (Rachmilewitz) without endoscopy)

    Time frame: 6 weeks post baseline

  6. Change in C-reactive protein, ESR, IL-3, IL-6 and IL-11 and calprotectin.

    Change in C-reactive protein, ESR, IL-3, IL-6 and IL-11 and calprotectin.

    Time frame: 6 weeks post baseline

  7. Adverse Events

    Adverse Events (AE): type, nature, incidence and outcome.

    Time frame: 6 weeks post baseline

  8. Vital signs

    Vital signs (axillary temperature, blood pressure and heart rate).

    Time frame: 6 weeks post baseline

  9. Physical examinations

    Physical examinations

    Time frame: 6 weeks post baseline

  10. Clinical laboratory panels

    Clinical laboratory panels (haematology/coagulation, clinical chemistry/inflammation, urinalysis).

    Time frame: 6 weeks post baseline

  11. Discontinuation of treatment due to AEs

    • Discontinuation of treatment due to AEs

    Time frame: 6 weeks post baseline

  12. Pregnancy test

    Pregnancy test

    Time frame: Visit 4

  13. CDAI/CAI

    CDAI/CAI

    Time frame: 6 weeks post baseline

07

Study locations

1 site
  • Univ. clinic for Internal Medicine
    Vienna, 1090, Austria
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2009
First posted
Apr 16, 2009
Start
Dec 2006
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Last update
Apr 8, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00882414
Lead sponsor
Vifor Pharma
First posted
Apr 16, 2009
Start date
Dec 2006
Primary completion
Jan 2010
Completion
Jan 2010
Last update
Apr 8, 2010

Study contacts

Christoph Gasche, MD
principal investigator · Allgemeines KrankenHaus, Vienna, Austria

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion